warfarin and Liver-Failure

warfarin has been researched along with Liver-Failure* in 4 studies

Reviews

1 review(s) available for warfarin and Liver-Failure

ArticleYear
A review of indications and comorbidities in which warfarin may be the preferred oral anticoagulant.
    Journal of clinical pharmacy and therapeutics, 2021, Volume: 46, Issue:3

    Direct oral anticoagulants (DOACs) are increasingly prescribed instead of warfarin for chronic anticoagulation for ease of dosing, fewer interactions, and less stringent monitoring. However, it is important to consider indications and comorbidities for which warfarin is still the preferred anticoagulant. This review aims to capture these clinical scenarios in which warfarin may still be preferred over DOACs.. We undertook a comprehensive literature search using the PubMed database. Key search terms were based on DOAC clinical trial exclusion criteria, as well as indications and conditions in which the use of DOACs for anticoagulation has suggested harm. Society guidelines and tertiary literature were used to inform expert opinion where necessary. Studies were included if they investigated the use of DOACs or warfarin in the identified indications or conditions.. Currently, evidence for the use of warfarin over DOACs for anticoagulation is strongest for patients with prosthetic valves, antiphospholipid syndrome, or a high risk of gastrointestinal bleeding. For several clinical situations, including mitral stenosis, obesity, altered gastrointestinal anatomy, pulmonary arterial hypertension, renal or hepatic impairment, and left ventricular thrombus, evidence is lacking but may eventually support the use of DOACs. Depending on indication and condition, appropriateness of DOAC use may vary by agent.. New evidence continues to support new indications and conditions in which DOACs may be appropriate to use for anticoagulation. There are key clinical scenarios, however, in which emerging literature continues to support warfarin as the preferred anticoagulant.

    Topics: Anticoagulants; Antiphospholipid Syndrome; Atrial Fibrillation; Blood Coagulation; Comorbidity; Drug Interactions; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Heart Valve Prosthesis; Humans; Liver Failure; Medication Adherence; Mitral Valve Stenosis; Overweight; Pulmonary Arterial Hypertension; Renal Insufficiency; Stroke; Warfarin

2021

Other Studies

3 other study(ies) available for warfarin and Liver-Failure

ArticleYear
Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis.
    European journal of gastroenterology & hepatology, 2016, Volume: 28, Issue:1

    Portal vein thrombosis (PVT) is a frequent event in patients with cirrhosis. The effects of anticoagulation on these patients were still unclear, especially for more advanced PVT. The aim of this study was to retrospectively assess the resolution of PVT and liver disease progression in a large cohort of cirrhotic patients with PVT with or without anticoagulation therapy.. We analyzed data from 66 cirrhotic patients with PVT from January 2002 to June 2014. Thirty patients were anticoagulated with warfarin and 36 patients were untreated. PVT and hepatic decompensation were evaluated.. For anticoagulated patients, the thrombosis had improved in 15 (68.2%) patients, was stable in four patients (18.2%), and progressed in three patients (13.6%). For untreated patients, the thrombosis had improved in four patients (25%), was stable in six patients (37.5%), and progressed in six patients (37.5%). The anticoagulation group had significantly better recanalization rates than the untreated group (P=0.011). Degree of superior mesenteric vein (P=0.032, hazard ratio: 15.4; 95% confidence interval: 1.3-200) was a significant predictor. In addition, anticoagulation can effectively improve PVT with a degree less than 75% in the main portal vein compared with untreated patients (6/6 vs. 2/6, P=0.030). The probability of hepatic decompensation at 1 year was 15.6 and 17.9% between the anticoagulation and the untreated groups (P=0.847). Albumin (P=0.06, hazard ratio: 0.860; 95% confidence interval: 0.772-0.959) was a significant predictor.. Anticoagulation with warfarin might result in the resolution of more advanced PVT effectively and safely in patients with liver cirrhosis. In addition, we did not demonstrate the benefit of anticoagulation for the decompensation or death.

    Topics: Adult; Anticoagulants; Female; Humans; Liver Cirrhosis; Liver Failure; Male; Middle Aged; Portal Vein; Retrospective Studies; Serum Albumin; Thrombosis; Tomography, X-Ray Computed; Treatment Outcome; Warfarin

2016
Reversible hepatic decompensation in primary biliary cirrhosis due to hypercoagulability.
    Annals of internal medicine, 2007, Nov-06, Volume: 147, Issue:9

    Topics: Anticoagulants; Factor VIII; Female; Heterozygote; Humans; Liver Cirrhosis, Biliary; Liver Failure; Middle Aged; Mutation; Thrombophilia; Warfarin

2007
Predicting abnormal coagulation in ischemic stroke: reducing delay in rt-PA use.
    Neurology, 2006, Nov-14, Volume: 67, Issue:9

    Normal prothrombin time (PT) and partial thromboplastin time (PTT) are recommended for administration of recombinant tissue-plasminogen activator (rt-PA) in stroke, but waiting for results can delay use. We examined the charts of 365 stroke patients to assess predetermined risk factors associated with elevated PT/PTT. Elevated PT/PTT can be predicted in patients taking warfarin or heparin/heparinoid or on hemodialysis, according to emergency department triage, with 100% sensitivity and 94.7% specificity. These results could be applied to rt-PA candidates and reduce potential delays.

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antiphospholipid Syndrome; Brain Ischemia; Coagulation Protein Disorders; Female; Heparin; Humans; Kidney Failure, Chronic; Liver Failure; Male; Middle Aged; Partial Thromboplastin Time; Predictive Value of Tests; Prothrombin Time; Recombinant Proteins; Renal Dialysis; Stroke; Time Factors; Tissue Plasminogen Activator; Triage; Warfarin

2006